Liquid Biopsy Study Presented at ASCO Uncovers Somatic Mutations Consistent With Tissue-Based Tests | GenomeWeb

CHICAGO (GenomeWeb) – Blood-based liquid biopsies can uncover somatic mutation patterns and distributions similar to those found by directly testing tumor tissue samples, according to research presented at the American Society of Clinical Oncology meeting here this weekend.

Researchers from the University of California, liquid biopsy technology firm Guardant Health, and Vista Oncology examined somatic mutation patterns gleaned from liquid biopsies for more than 15,000 advanced cases, representing more than 50 cancer types, using Guardant Health's Guardant360 test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Feb
23
Sponsored by
NuGEN

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.